WebDec 7, 2024 · Based on the mechanism of action, DARZALEX FASPRO TM can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO TM may cause depletion of fetal immune cells and decreased bone ... WebApr 19, 2024 · Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through ...
Darzalex Faspro: Side effects and how to manage them - Medical …
WebIn some cases, health care professionals may use the trade name DARZALEX FASPRO or the generic name Daratumumab and Hyaluronidase when referring to the drug. Drug … Mechanism of action Daratumumab is an IgG1k monoclonal antibody directed against CD38. CD38 is overexpressed in multiple myeloma cells. Daratumumab binds to a different CD38 epitope amino-acid sequence than does the anti-CD38 monoclonal antibody isatuximab. Daratumumab binds to CD38, … See more Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally … See more In May 2024, the U.S. Food and Drug Administration (FDA) approved daratumumab for use in combination with bortezomib, melphalan and prednisone to include the … See more With blood compatibility testing Daratumumab can also bind to CD38 present on red blood cells and interfere with routine testing for clinically significant antibodies. People will show a panreactive antibody panel, including a positive auto-control, which … See more • "Daratumumab". Drug Information Portal. U.S. National Library of Medicine. See more Treatment of multiple myeloma with daratumumab potentially increases the patient's susceptibility to bacterial and viral infections, due to the killing of natural killer cells (which are the main innate immune system defense against virus). Daratumumab … See more Encouraging preliminary results were reported in June 2012, from a Phase I/II clinical trial in relapsed multiple myeloma participants. Updated trial results presented in … See more spedition vertex
HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEX …
WebJun 4, 2024 · DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in ... WebMay 26, 2024 · Based on the mechanism of action, DARZALEX FASPRO™ can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO™ may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Webmyeloma who received DARZALEX FASPRO-Pd are fatigue, pneumonia, upper respiratory tract infection, and diarrhea (6.1) • The most common adverse reactions (≥20%) in … spedition vilshofen